HBOT administration resulted in measurable reductions in CCT and corneal volume, along with an increase in anterior chamber volume, in all treated eyes. The observed decrease in corneal thickness manifested less prominently in diabetic patients compared to their non-diabetic counterparts, suggesting potential metabolic influences on corneal response to hyperoxic conditions.